Experience with siponimod for treating patients with secondary progressive multiple sclerosis in the Moscow Region
Siponimod is a sphingosine-1-phosphate receptor modulator approved in most countries for the treatment of secondary progressive multiple sclerosis (SPMS) with activity. The EXPAND study showed that the drug effectively reduces disease activity at the peripheral level by preventing autoreactive immun...
Збережено в:
| Автори: | , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Russo |
| Опубліковано: |
IMA-PRESS LLC
2025-12-01
|
| Серія: | Неврология, нейропсихиатрия, психосоматика |
| Предмети: | |
| Онлайн доступ: | https://nnp.ima-press.net/nnp/article/view/2740 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|